← Evidence map

ArticleHepatobiliary surgery and nutrition2026

Neoadjuvant immuno-chemotherapy combined with antiangiogenic therapy for patients with resectable high-risk intrahepatic cholangiocarcinoma and excellent performance status: interim efficacy results from the ZSAB-neoGOLP trial.

Marco Gerling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Neoadjuvant immuno-chemotherapy combined with antiangiogenic therapy for patients with resectable high-risk intrahepatic cholangiocarcinoma and excellent performance status: interim efficacy results from the ZSAB-neoGOLP trial. | OpenQuestion